Kommentar

• Literatur

• 1 Kekre N, Tokessy M, Mallick R. et al. Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?. Biol Blood Marrow Transplant 2013; 19: 1719-1724
• 2 Hall S, Danby R, Osman H. et al. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience. Transfus Med 2015; 25: 418-423
• 3 Nash T, Hoffmann S, Butch S. et al. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion 2012; 52: 2270-2272
• 4 Thiele T, Krüger W, Zimmermann K. et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion 2011; 51: 2620-2626
• 5 Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002; 42: 396-402